血脂异常老年人使用他汀类药物中国专家共识

血脂异常老年人使用他汀类药物中国专家共识

作者：血脂异常老年人使用他汀类药物中国专家共识组

作者单位：

刊名：

中华内科杂志

英文刊名：Chinese Journal of Internal Medicine

年，卷(期)：2015,54(5)

被引用次数：5次

参考文献(82条)

1.Yang G;Wang Y;Zeng Y Rapid health transition in China,1990-2010:findings from the Global Burden of Disease Study 2010 2013(9882)

2.Pilote L;Beck CA;Karp I Secondary prevention after acute myocardial infarction in four Canadian provinces,1997-2000 2004(1)

3.Al-Omran M;Mamdani MM;Lindsay TF Suboptimal use of statin therapy in elderly patients with atherosclerosis:a population-based study 2008(3)

4.血脂异常老年人使用他汀类药物中国专家共识组血脂异常老年人使用他汀类药物中国专家共识[期刊论文]-中华内科杂志

2010(6)

5.李剑虹,米生权,李镒冲,张梅,毕宇芳,姜勇,王丽敏,宁光,赵文华2010年我国成年人血脂水平及分布特征[期刊论文]-中华预防医学杂志 2012(7)

6.Yang W;Xiao J;Yang Z Serum lipids and lipoproteins in Chinese men and women 2012(18)

7.He J;Gu D;Reynolds K Serum total and lipoprotein cholesterol levels and awareness,treatment,and control of hypercholesterolemia in China 2004(4)

8.Downs JR;Clearfield M;Weis S Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study 1998(20)

9.Sever PS;Dahl(o)f B;Poulter NR Prevention of coronary and stroke events with atorvastatin in hypertensive

patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial 2003(9346)

10.Lemaitre RN;Psaty BM;Heckbert SR Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults:evidence from the Cardiovascular Health Study 2002(12)

11.Mehta JL;Bursac Z;Hauer-Jensen M Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population 2006(7)

12.Ridker PM;Danielson E;Fonseca FA Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein 2008(21)

13.Glynn RJ;Koenig W;Nordestgaard BG Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels:exploratory analysis of a randomized trial 2010(8)

14.Packard CJ;Ford I;Murray H Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year follow-up of the West of Scotland Coronary Prevention Study 2014

15.Nohara R;Daida H;Hata M Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intimamedia thickness in Japanese patients:Justification for Atherosclerosis Regression Treatment (JART) study 2012(1)

16.Nohara R;Daida H;Hata M Effect of long-term intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness-justification for Atherosclerosis Regression Treatment (JART) extension study

2013(6)

17.冯雪茹,张婧薇,刘梅林,李雪迎瑞舒伐他汀对中国颈动脉粥样硬化患者内中膜厚度和安全性的荟萃分析[期刊论文]-中华心血管病杂志 2014(3)

18.Miettinen TA;Py(o)r(a)l(a) K;Olsson AG Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris:findings from the Scandinavian Simvastatin Survival Study (4S) 1997(12) 19.Lewis SJ;Moye LA;Sacks FM Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range.Results of the Cholesterol and Recurrent Events (CARE) trial 1998(9)

20.Hunt D;Young P;Simes J Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients:Results from the LIPID trial 2001(10) 21.Heart Protection Study Collaborative Group The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people:a randomized placebo-controlled trial 2005 22.Pedersen TR;Faergeman O;Kastelein J J High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial 2005(19)

23.Wenger NK;Lewis SJ;Herrington DM Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease 2007(1)

24.Ye P;Lu ZL;Du BM Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction:a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study 2007(7)

25.Shepherd J;Blauw GJ;Murphy MB Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial 2002(9346)

26.Lloyd SM;Stott D J;de Craen A J Long-term effects of statin treatment in elderly people:extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) 2013(9)

27.Deedwania P;Stone PH;Bairey Merz CN Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease:results of the Study Assessing Goals in the Elderly (SAGE) 2007(6)

28.Athyros VG;Katsiki N;Tziomalos K Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease:a post hoe analysis of the GREACE study 2013(3)

29.Olsson AG;Schwartz GG;Szarek M Effects of high-dose atorvastatin in patients 》 or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering[MIRACL]study)

2007(5)

30.de Lemos JA;Blazing MA;Wiviott SD Early intensive vs a delayed conservative simvastatin strategy in patients

with acute coronary syndromes:phase Z of the A to Z trial 2004(11)

31.Cannon CP;Braunwald E;McCabe CH Intensive versus moderate lipid lowering with statins after acute coronary syndromes 2004(15)

32.Ray KK;Bach RG;Cannon CP Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS

2006(19)

33.Gransbo K;Melander O;Wallentin L Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment 2010(13)

34.Blazing MA;Giugliano RP;Cannon CP Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes:final baseline characteristics of the IMPROVE-IT study population 2014(2)

myocardial infarction:evidence for an age-statin interaction 2006(3)

36.Cooke CA;Kirkland SA;Sketris IS The impact of statins on health services utilization and mortality in older adults discharged from hospital with ischemic heart disease:a cohort study 2009

37.Eaton CB;Lapane KL;Murphy JB Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes 2002(8)

38.Aronow WS;Ahn C Incidence of new coronary events in older persons with prior myocardial infarction and serum

low-density lipoprotein cholesterol 》 or =125 mg/dl treated with statins versus no lipid-lowering drug 2002(1) 39.Allen Maycock CA;Muhlestein JB;Horne BD Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease,including very elderly patients 2002(10)

40.Mizuno K;Nakaya N;Ohashi Y Usefulness of pravastatin in primary prevention of cardiovascular events in

women:analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study) 2008(4)

41.Collins R;Armitage J;Parish S MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomized placebo-controlled trial 2003(9374)

42.Neil HA;DeMicco DA;Luo D Analysis of efficacy and safety in patients aged 65-75 years at

randomization:Collaborative Atorvastatin Diabetes Study (CARDS) 2006(11)

43.Cholesterol Treatment Trialists' (CTT) Collaborators;Kearney PM;Blackwell L Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis 2008(9607)

44.Holdaas H;Holme I;Schmieder RE Rosuvastatin in diabetic hemodialysis patients 2011(7)

45.Olafsdottir E;Aspelund T;Sigurdsson G Effects of statin medication on mortality risk associated with type 2 diabetes in older persons:the population-based AGES-Reykjavik Study 2011(1)

46.Culver AL;Ockene IS;Balasubramanian R Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative 2012(2)

47.Sattar N;Preiss D;Murray HM Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials 2010(9716)

48.Preiss D;Seshasai SR;Welsh P Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta-analysis 2011(24)

49.Kjekshus J;Apetrei E;Barrios V Rosuvastatin in older patients with systolic heart failure 2007(22)

50.Shah R;Wang Y;Foody JM Effect of statins,angiotensin-converting enzyme inhibitors,and beta blockers on survival in patients 》 or =65 years of age with heart failure and preserved left ventricular systolic function 2008(2)

51.Bernick C;Katz R;Smith NL Statins and cognitive function in the elderly:the Cardiovascular Health Study 2005(9)

52.Trompet S;van Vliet P;de Craen AJ Pravastatin and cognitive function in the elderly.Results of the PROSPER study 2010(1)

53.Ott BR;Daiello LA;Dahabreh IJ Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials 2015(3)

54.Swiger K J;Manalac R J;Blumenthal RS Statins and cognition:a systematic review and meta-analysis of short-and long-term cognitive effects 2013(11)

55.Collins R;Armitage J;Parish S Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions 2004(9411)

56.Amarenco P;Boqousslavsky J;Callahan A 3rd High-dose atorvastatin after stroke or transient ischemic attack

2006(6)

57.Goldstein LB;Amarenco P;Szarek M Hemorrhagic stroke in the stroke prevention by aggressive reduction in

58.Baigent C;Landray MJ;Reith C The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial 2011(9784) 59.Herrington W;Emberson J;Staplin N The effect of lowering LDL cholesterol on vascular access patency:post hoc analysis of the Study of Heart and Renal Protection 2014(5)

60.Hou W;Lv J;Perkovic V Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease:a systematic review and meta-analysis 2013(24)

61.Wu Y;Wang Y;An C Effects of rosuvastatin and atorvastatin on renal function:meta-analysis 2012(5)

62.Savarese G;Musella F;Volpe M Effects of atorvastatin and rosuvastatin on renal function:a meta-analysis 2013(6)

63.Navaneethan SD;Pansini F;Perkovic V HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis 2009(2)

64.Afilalo J;Duque G;Steele R Statins for secondary prevention in elderly patients:a hierarchical bayesian meta-analysis 2008(1)

65.Savarese G;Gotto AM Jr;Paolillo S Benefits of statins in elderly subjects without established cardiovascular disease:a meta-analysis 2013(22)

66.Yan YL;Qiu B;Hu LJ Efficacy and safety evaluation of intensive statin therapy in older patients with coronary heart disease:a systematic review and meta-analysis 2013(12)

67.中国成人血脂异常防治指南制订联合委员会中国成人血脂异常防治指南[期刊论文]-中华心血管病杂志 2007(5)

68.2014年中国胆固醇教育计划血脂异常防治建议专家组,中华心血管病杂志编辑委员会,血脂与动脉粥样硬化循证工作组,中华医学会心血管病学分会流行病学组2014年中国胆固醇教育计划血脂异常防治专家建议[期刊论文]-中华心血管病杂志 2014(8)

69.Jacobson TA;Ito MK;Maki KC National Lipid Association recommendations for patient-centered management of dyslipidemia:part 1-executive summary 2014(5)

70.Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An International Atherosclerosis Society Position Paper:global recommendations for the management of dyslipidemia--full report

2014(1)

71.Stone NJ;Robinson JG;Lichtenstein AH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2014(25 Suppl 2)

72.Rabar S;Harker M;O' Flynn N Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease:summary of updated NICE guidance 2014

73.他汀类药物安全性评价工作组他汀类药物安全性评价专家共识[期刊论文]-中华心血管病杂志 2014(11)

74.Tomaszewski M;St(e)pie(n) KM;Tomaszewska J Statin-induced myopathies 2011(4)

75.Bays H;Cohen DE;Chalasani N An assessment by the Statin Liver Safety Task Force:2014 update 2014(3 Suppl)

76.Kellick KA;Bottorff M;Toth PP A clinician's guide to statin drug-drug interactions 2014(3 Suppl)

77.Tonelli M;Wanner C;Kidney Disease:Improving Global Outcomes Lipid Guideline Development Work Group Members

Lipid management in chronic kidney disease:synopsis of the Kidney Disease:Improving Global Outcomes 2013 clinical practice guideline 2014(3)

78.Maki KC;Ridker PM;Brown WV An assessment by the Statin Diabetes Safety Task Force:2014 update 2014(3 Suppl)

79.FDA Drug Safety Communication:Important Safety Label Changes to Cholesterol-Lowering Statin Drugs 2015

80.Rojas-Fernandez CH;Goldstein LB;Levey AI An assessment by the Statin Cognitive Safety Task Force:2014 update 2014(3 Suppl)

81.Feldman T;Davidson M;Shah A Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia:a post Hoc

82.Shalev V;Chodick G;Silber H Continuation of statin treatment and all-cause mortality:a population-based cohort study 2009(3)

引证文献(5条)

1.刘梅林重视老年人血脂异常管理[期刊论文]-中国医学前沿杂志（电子版） 2015(05)

2.田清平,刘梅林老年人调脂药物与其他常用药物的相互作用[期刊论文]-中国医学前沿杂志（电子版） 2015(05)

3.范琰,陈亚红,刘梅林老年人血脂异常的治疗原则和药物选择[期刊论文]-中国医学前沿杂志（电子版） 2015(05)

4.谭喜莹,李静因药物相互作用引起横纹肌溶解1例报告[期刊论文]-上海医药 2015(13)

5.冯雪茹,刘梅林老年人使用他汀类药物一级预防的建议[期刊论文]-中国医学前沿杂志（电子版） 2015(05)

引用本文格式：血脂异常老年人使用他汀类药物中国专家共识组血脂异常老年人使用他汀类药物中国专家共识[期刊论文]-中华内科杂志 2015(5)